BioTissue Holdings, Inc. is the pioneer and leader in regenerative medicine for ocular surface disease and injury, as well as ocular hygiene solutions for eye care professionals. Established in 1997, BioTissue serves an unmet need for better surgical and therapeutic alternatives for helping eye care professionals manage ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis (CCH) also known as mechanical dry eye, pterygium and severe dry eye. Eye care professionals understand that good medicine is based on good science. BioTissue prides itself on developing products that meet the highest clinical standards, are based on quality research and scientific data, and provide innovative solutions for the management of a range of ocular surface and lid margin diseases. BioTissue adheres to the FDA tissue and medical device guidelines. BioTissue offers the only commercially available amniotic membrane that preserves the native integrity, activity, and function exhibited by the tissue in utero for ocular surface wound repair and wound healing. Our proprietary processing and preservation method retains vital cytokines and growth factors which facilitate healing mechanisms such as: • Anti-inflammatory • Anti-scarring • Anti-angiogenic • Pain reduction • Promotion of epithelial healing